167 related articles for article (PubMed ID: 38674115)
21. Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/β-catenin signaling regulation.
Shome R; Ghosh SS
Cell Oncol (Dordr); 2021 Apr; 44(2):405-422. PubMed ID: 33398673
[TBL] [Abstract][Full Text] [Related]
22. Neferine sensitized Taxol-resistant nasopharygeal carcinoma to Taxol by inhibiting EMT via downregulating miR-130b-5p.
Wang X; Wang K; Xiao J; Song Y; Li H
Biochem Biophys Res Commun; 2020 Oct; 531(4):573-580. PubMed ID: 32811645
[TBL] [Abstract][Full Text] [Related]
23. Cancer-Associated Fibroblasts Autophagy Enhances Progression of Triple-Negative Breast Cancer Cells.
Wang M; Zhang J; Huang Y; Ji S; Shao G; Feng S; Chen D; Zhao K; Wang Z; Wu A
Med Sci Monit; 2017 Aug; 23():3904-3912. PubMed ID: 28802099
[TBL] [Abstract][Full Text] [Related]
24. Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rb-E2F signaling and epithelial-mesenchymal transition.
Wang W; Zhang R; Wang X; Wang N; Zhao J; Wei Z; Xiang F; Wang C
Cancer Sci; 2020 Apr; 111(4):1422-1434. PubMed ID: 32011034
[TBL] [Abstract][Full Text] [Related]
25. Antrodia camphorata inhibits epithelial-to-mesenchymal transition by targeting multiple pathways in triple-negative breast cancers.
Hseu YC; Chang GR; Pan JY; Rajendran P; Mathew DC; Li ML; Liao JW; Chen WT; Yang HL
J Cell Physiol; 2019 Apr; 234(4):4125-4139. PubMed ID: 30146779
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition.
Garcia E; Luna I; Persad KL; Agopsowicz K; Jay DA; West FG; Hitt MM; Persad S
Sci Rep; 2021 Jun; 11(1):11757. PubMed ID: 34083676
[TBL] [Abstract][Full Text] [Related]
27. CHD4-mediated loss of E-cadherin determines metastatic ability in triple-negative breast cancer cells.
Luo CW; Wu CC; Chang SJ; Chang TM; Chen TY; Chai CY; Chang CL; Hou MF; Pan MR
Exp Cell Res; 2018 Feb; 363(1):65-72. PubMed ID: 29305962
[TBL] [Abstract][Full Text] [Related]
28. Long non-coding RNA ZEB2-AS1 promotes the proliferation, metastasis and epithelial mesenchymal transition in triple-negative breast cancer by epigenetically activating ZEB2.
Zhang G; Li H; Sun R; Li P; Yang Z; Liu Y; Wang Z; Yang Y; Yin C
J Cell Mol Med; 2019 May; 23(5):3271-3279. PubMed ID: 30825262
[TBL] [Abstract][Full Text] [Related]
29. Silencing of Prrx1b suppresses cellular proliferation, migration, invasion and epithelial-mesenchymal transition in triple-negative breast cancer.
Lv ZD; Yang ZC; Liu XP; Jin LY; Dong Q; Qu HL; Li FN; Kong B; Sun J; Zhao JJ; Wang HB
J Cell Mol Med; 2016 Sep; 20(9):1640-50. PubMed ID: 27027510
[TBL] [Abstract][Full Text] [Related]
30. Transferrin Coated d-penicillamine-Au-Cu Nanocluster PLGA Nanocomposite Reverses Hypoxia-Induced EMT and MDR of Triple-Negative Breast Cancers.
Shome R; Ghosh SS
ACS Appl Bio Mater; 2021 Jun; 4(6):5033-5048. PubMed ID: 35007052
[TBL] [Abstract][Full Text] [Related]
31. MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer.
Oudin MJ; Barbier L; Schäfer C; Kosciuk T; Miller MA; Han S; Jonas O; Lauffenburger DA; Gertler FB
Mol Cancer Ther; 2017 Jan; 16(1):143-155. PubMed ID: 27811011
[TBL] [Abstract][Full Text] [Related]
32. Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer.
Hata T; Rajabi H; Yamamoto M; Jin C; Ahmad R; Zhang Y; Kui L; Li W; Yasumizu Y; Hong D; Miyo M; Hiraki M; Maeda T; Suzuki Y; Takahashi H; Samur M; Kufe D
Mol Cancer Ther; 2019 Oct; 18(10):1744-1754. PubMed ID: 31308076
[TBL] [Abstract][Full Text] [Related]
33. Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the β-catenin signaling pathway.
Huang J; Yang B; Xiang T; Peng W; Qiu Z; Wan J; Zhang L; Li H; Li H; Ren G
Mol Nutr Food Res; 2015 Jun; 59(6):1063-75. PubMed ID: 25755089
[TBL] [Abstract][Full Text] [Related]
34. Dihydrotanshinone-I modulates Epithelial Mesenchymal Transition (EMT) Thereby Impairing Migration and Clonogenicity of Triple Negative Breast Cancer Cells.
Kashyap A; Umar SM; Dev J R A; Prasad CP
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2177-2184. PubMed ID: 34319041
[TBL] [Abstract][Full Text] [Related]
35. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
36. Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway.
Peng B; He R; Xu Q; Yang Y; Hu Q; Hou H; Liu X; Li J
Pharmacol Res; 2019 Apr; 142():1-13. PubMed ID: 30735802
[TBL] [Abstract][Full Text] [Related]
37. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR
Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
[TBL] [Abstract][Full Text] [Related]
38. Cancer-Associated MORC2-Mutant M276I Regulates an hnRNPM-Mediated CD44 Splicing Switch to Promote Invasion and Metastasis in Triple-Negative Breast Cancer.
Zhang FL; Cao JL; Xie HY; Sun R; Yang LF; Shao ZM; Li DQ
Cancer Res; 2018 Oct; 78(20):5780-5792. PubMed ID: 30093560
[TBL] [Abstract][Full Text] [Related]
39. An in vitro study on the reversal of epithelial to mesenchymal transition by brusatol and its synergistic properties in triple-negative breast cancer cells.
Chandrasekaran J; Balasubramaniam J; Sellamuthu A; Ravi A
J Pharm Pharmacol; 2021 Apr; 73(6):749-757. PubMed ID: 33769483
[TBL] [Abstract][Full Text] [Related]
40. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
Liu J; Chen X; Ward T; Pegram M; Shen K
Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
